Evaluation du site lifescivc.com
LifeSciVC - Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech.LifeSciVC | Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech.
Généré le 27 Mars 2026 06:27
Vieilles statistiques? UPDATE !
Le score est de 54/100
Optimisation du contenu
Titre
LifeSciVC - Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech.LifeSciVC | Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech.
Longueur : 188
Idéalement, votre titre devrait contenir entre 10 et 70 caractères (espaces compris). Utilisez cet outil gratuit pour calculer la longueur du texte.
Description
Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech.
Longueur : 82
Génial, votre balise META description contient entre 70 et 160 caractères.
Mots-clefs
Très mauvais. Nous n'avons pas trouvé de balise META keywords sur votre page. Utilisez ce générateur gratuit de balises META en ligne pour créer des mots-clés.
Propriétés Open Graph
Bien, cette page profite des balises META Open Graph.
| Propriété | Contenu |
|---|---|
| locale | en_US |
| type | website |
| title | LifeSciVC |
| description | Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech. |
| url | https://lifescivc.com/ |
| site_name | LifeSciVC |
Niveaux de titre
| H1 | H2 | H3 | H4 | H5 | H6 |
| 2 | 40 | 7 | 0 | 0 | 0 |
- [H1] Process-Driven Cadence: Biotech IPOs Demystified
- [H1] Atlas Venture 2025 Year In Review
- [H2] Twenty Years In Early Stage Biotech VC (Part 3): BusinessOctober 16, 2025
- [H2] Twenty Years In Early Stage Biotech VC (Part 2): PeopleOctober 15, 2025
- [H2] Twenty Years In Early Stage Biotech VC (Part 1): ScienceOctober 14, 2025
- [H2] Biotech Wisdom Of The Crowds: Competition And CapitalismMay 28, 2025
- [H2] Biotech Venture Creation: The Benefits Of ScarcityApril 8, 2025
- [H2] Atlas XIV And Reflections On The VC Math ProblemDecember 5, 2024
- [H2] Atlas Venture 2024 Year In ReviewNovember 18, 2024
- [H2] Biotech Risk Cycles: Assets And PlatformsOctober 28, 2024
- [H2] A Molecular Biologist’s Advice For LifeJuly 1, 2024
- [H2] Mariana Oncology’s Radiopharm Platform Acquired By NovartisMay 6, 2024
- [H2] The Biotech Startup Contraction Continues… And That’s A Good ThingApril 26, 2024
- [H2] IFM’s Hat Trick and Reflections On Option-To-Buy M&AMarch 13, 2024
- [H2] Biotech Venture Ecosystem: Quick Health CheckJanuary 12, 2024
- [H2] Biotech Consolidation: Not Really HappeningNovember 30, 2023
- [H2] Atlas Venture 2023 Year In ReviewNovember 17, 2023
- [H2] Biotech Funding: Times Are Tough, Maybe For The BetterApril 14, 2023
- [H2] Science2Startup 2023: Innovation And EntrepreneurshipFebruary 28, 2023
- [H2] Takeda Acquires Nimbus’ Tyk2 Autoimmune ProgramDecember 13, 2022
- [H2] Atlas Venture 2022 Year In ReviewNovember 7, 2022
- [H2] Surprising Resilience Of Private VC-Backed Biotech MarketsJuly 6, 2022
- [H2] Responding To Tough Markets: Restructurings In BiotechApril 14, 2022
- [H2] Biotech’s January Chill: Big Drop In New StartupsApril 4, 2022
- [H2] In Defense Of Early Stage Biotech IPOsMarch 28, 2022
- [H2] Innovation Ecosystem: A Year Of Risk-Off CorrelationsMarch 21, 2022
- [H2] Biotech Bears: Jumping A Lower Bar Or A Higher One?March 17, 2022
- [H2] Getting Public Is Easy, Being Public Is HardNovember 18, 2021
- [H2] State of the Industry: 2021 Year In ReviewNovember 16, 2021
- [H2] Biotech’s Relevancy Challenge In An Expanding UniverseJune 1, 2021
- [H2] Five Macro Risks To Biotech Coming Out of WashingtonApril 22, 2021
- [H2] Biotech Funding Tops The Charts AgainApril 20, 2021
- [H2] Personal Reflection: Empathy In The WorkplaceMarch 16, 2021
- [H2] The Biotech Paradox of 2020: A Year In ReviewJanuary 4, 2021
- [H2] Biotech: The Featherweight Champion Of The MarketsNovember 20, 2020
- [H2] It’s Raining Biotech SPACs!October 15, 2020
- [H2] Evolution Of The Biotech IPO Markets From Busted To BoomingSeptember 21, 2020
- [H2] Kymera Debuts On The Public MarketsAugust 31, 2020
- [H2] The Record-Breaking Biotech Funding Tsunami Of 1H2020July 15, 2020
- [H2] Value Creation And Destruction: Dispersion of Performance In Biotech IPOsApril 17, 2020
- [H2] Booming VC-Backed Biopharma: Strong Market Despite PandemicApril 8, 2020
- [H2] Strategic Planning In Biotech During A Pandemic CrisisMarch 26, 2020
- [H3] search
- [H3] subscribe by email
- [H3] Twitter
- [H3] Recent Posts
- [H3] current comments
- [H3] topics
- [H3] monthly archive
Images
Nous avons trouvé 9 image(s) sur cette page Web.
3 attribut(s) alt sont vides ou manquants. Ajouter un texte alternatif permet aux moteurs de recherche de mieux comprendre le contenu de vos images.
Ratio texte/HTML
Ratio : 17%
Bien, le ratio de cette page texte/HTML est supérieur à 15, mais inférieur à 25 pour cent.
Flash
Parfait, aucun contenu FLASH n'a été détecté sur cette page.
Iframe
Génial, il n'y a pas d'Iframes détectés sur cette page.
Liens
Réécriture d'URLs
Bien. Vos liens sont optimisés!
Tiret bas dans les URLs
Nous avons détectés des soulignements dans vos URLs. Vous devriez plutôt utiliser des tirets pour optimiser votre référencement.
Liens dans la page
Nous avons trouvé un total de 289 lien(s) dont 0 lien(s) vers des fichiers
| Texte d'ancre | Type | Juice |
|---|---|---|
| Blog | Interne | Passing Juice |
| About Me | Interne | Passing Juice |
| From The Trenches | Interne | Passing Juice |
| Process-Driven Cadence: Biotech IPOs Demystified | Interne | Passing Juice |
| Capital markets | Interne | Passing Juice |
| Exits IPOs M&As | Interne | Passing Juice |
| - | Externe | Passing Juice |
| - | Externe | Passing Juice |
| - | Externe | Passing Juice |
| - | Externe | Passing Juice |
| - | Externe | Passing Juice |
| how fundamentally it changed the IPO process | Interne | Passing Juice |
| Comment | Interne | Passing Juice |
| Atlas Venture 2025 Year In Review | Interne | Passing Juice |
| Atlas Venture | Interne | Passing Juice |
| Biotech financing | Interne | Passing Juice |
| Drug discovery | Interne | Passing Juice |
| Pharma industry | Interne | Passing Juice |
| Pricing and Policy | Interne | Passing Juice |
| R&D Productivity | Interne | Passing Juice |
| Science & Medicine | Interne | Passing Juice |
| - | Externe | Passing Juice |
| - | Externe | Passing Juice |
| - | Externe | Passing Juice |
| - | Externe | Passing Juice |
| - | Externe | Passing Juice |
| 2024 | Interne | Passing Juice |
| 2023 | Interne | Passing Juice |
| 2022 | Interne | Passing Juice |
| 2021 | Interne | Passing Juice |
| 2020 | Interne | Passing Juice |
| 2019 | Interne | Passing Juice |
| 2018 | Interne | Passing Juice |
| Comment | Interne | Passing Juice |
| Twenty Years In Early Stage Biotech VC (Part 3): Business | Interne | Passing Juice |
| Twenty Years In Early Stage Biotech VC (Part 2): People | Interne | Passing Juice |
| Twenty Years In Early Stage Biotech VC (Part 1): Science | Interne | Passing Juice |
| Biotech Wisdom Of The Crowds: Competition And Capitalism | Interne | Passing Juice |
| Biotech Venture Creation: The Benefits Of Scarcity | Interne | Passing Juice |
| Atlas XIV And Reflections On The VC Math Problem | Interne | Passing Juice |
| Biotech Risk Cycles: Assets And Platforms | Interne | Passing Juice |
| A Molecular Biologist’s Advice For Life | Interne | Passing Juice |
| Mariana Oncology’s Radiopharm Platform Acquired By Novartis | Interne | Passing Juice |
| The Biotech Startup Contraction Continues… And That’s A Good Thing | Interne | Passing Juice |
| IFM’s Hat Trick and Reflections On Option-To-Buy M&A | Interne | Passing Juice |
| Biotech Venture Ecosystem: Quick Health Check | Interne | Passing Juice |
| Biotech Consolidation: Not Really Happening | Interne | Passing Juice |
| Biotech Funding: Times Are Tough, Maybe For The Better | Interne | Passing Juice |
| Science2Startup 2023: Innovation And Entrepreneurship | Interne | Passing Juice |
| Takeda Acquires Nimbus’ Tyk2 Autoimmune Program | Interne | Passing Juice |
| Surprising Resilience Of Private VC-Backed Biotech Markets | Interne | Passing Juice |
| Responding To Tough Markets: Restructurings In Biotech | Interne | Passing Juice |
| Biotech’s January Chill: Big Drop In New Startups | Interne | Passing Juice |
| In Defense Of Early Stage Biotech IPOs | Interne | Passing Juice |
| Innovation Ecosystem: A Year Of Risk-Off Correlations | Interne | Passing Juice |
| Biotech Bears: Jumping A Lower Bar Or A Higher One? | Interne | Passing Juice |
| Getting Public Is Easy, Being Public Is Hard | Interne | Passing Juice |
| Biotech’s Relevancy Challenge In An Expanding Universe | Interne | Passing Juice |
| Five Macro Risks To Biotech Coming Out of Washington | Interne | Passing Juice |
| Biotech Funding Tops The Charts Again | Interne | Passing Juice |
| Personal Reflection: Empathy In The Workplace | Interne | Passing Juice |
| Biotech: The Featherweight Champion Of The Markets | Interne | Passing Juice |
| It’s Raining Biotech SPACs! | Interne | Passing Juice |
| Kymera Debuts On The Public Markets | Interne | Passing Juice |
| The Record-Breaking Biotech Funding Tsunami Of 1H2020 | Interne | Passing Juice |
| Value Creation And Destruction: Dispersion of Performance In Biotech IPOs | Interne | Passing Juice |
| Booming VC-Backed Biopharma: Strong Market Despite Pandemic | Interne | Passing Juice |
| Strategic Planning In Biotech During A Pandemic Crisis | Interne | Passing Juice |
| Tweets by @LifeSciVC | Externe | Passing Juice |
| Balancing the Risks and Rewards of Drug Development in China: A Small Biotech CEO Perspective | Interne | Passing Juice |
| Ex-US Clinical Trials: Tribulations, Preparations, and Expectations | Interne | Passing Juice |
| Dual Wielding in I&I: A Pivotal Year Ahead | Interne | Passing Juice |
| Why Owning the Learning Loop Matters More Than Owning the Lab | Interne | Passing Juice |
| Two’s Company, Three’s Diversity | Interne | Passing Juice |
| Two’s Company, Three’s Diversity | Interne | Passing Juice |
| AliFarquhar | Externe | Passing Juice |
| Two’s Company, Three’s Diversity | Interne | Passing Juice |
| When Does Digital Health Become Just Healthcare? | Interne | Passing Juice |
| We Saw It Coming In Pharma: Now Gene Therapy Is Biotech 2.0 For Rare Diseases | Interne | Passing Juice |
| #RunningAtlas | Interne | Passing Juice |
| Adaptive Sports | Interne | Passing Juice |
| Bioentrepreneurship | Interne | Passing Juice |
| Biotech investment themes | Interne | Passing Juice |
| Biotech startup advice | Interne | Passing Juice |
| Boards and governance | Interne | Passing Juice |
| Boston Cluster | Interne | Passing Juice |
| Business Development | Interne | Passing Juice |
| Capital efficiency | Interne | Passing Juice |
| China | Interne | Passing Juice |
| Corporate Culture | Interne | Passing Juice |
| Diagnostics | Interne | Passing Juice |
| External R&D | Interne | Passing Juice |
| FDA | Interne | Passing Juice |
| From The Trenches | Interne | Passing Juice |
| Fundraising | Interne | Passing Juice |
| General Venture Capital | Interne | Passing Juice |
| Governance | Interne | Passing Juice |
| Leadership | Interne | Passing Juice |
| Marketing | Interne | Passing Juice |
| New business models | Interne | Passing Juice |
| Patients | Interne | Passing Juice |
| Personal | Interne | Passing Juice |
| Personalized Medicine | Interne | Passing Juice |
| Portfolio news | Interne | Passing Juice |
| Rare Diseases | Interne | Passing Juice |
| Strategy | Interne | Passing Juice |
| Talent | Interne | Passing Juice |
| The Human Element | Interne | Passing Juice |
| Translational research | Interne | Passing Juice |
| Uncategorized | Interne | Passing Juice |
| VC-backed Biotech Returns | Interne | Passing Juice |
| March 2026 | Interne | Passing Juice |
| February 2026 | Interne | Passing Juice |
| January 2026 | Interne | Passing Juice |
| December 2025 | Interne | Passing Juice |
| November 2025 | Interne | Passing Juice |
| October 2025 | Interne | Passing Juice |
| September 2025 | Interne | Passing Juice |
| August 2025 | Interne | Passing Juice |
| July 2025 | Interne | Passing Juice |
| June 2025 | Interne | Passing Juice |
| May 2025 | Interne | Passing Juice |
| April 2025 | Interne | Passing Juice |
| March 2025 | Interne | Passing Juice |
| February 2025 | Interne | Passing Juice |
| January 2025 | Interne | Passing Juice |
| December 2024 | Interne | Passing Juice |
| November 2024 | Interne | Passing Juice |
| October 2024 | Interne | Passing Juice |
| September 2024 | Interne | Passing Juice |
| August 2024 | Interne | Passing Juice |
| July 2024 | Interne | Passing Juice |
| June 2024 | Interne | Passing Juice |
| May 2024 | Interne | Passing Juice |
| April 2024 | Interne | Passing Juice |
| March 2024 | Interne | Passing Juice |
| February 2024 | Interne | Passing Juice |
| January 2024 | Interne | Passing Juice |
| November 2023 | Interne | Passing Juice |
| October 2023 | Interne | Passing Juice |
| September 2023 | Interne | Passing Juice |
| August 2023 | Interne | Passing Juice |
| July 2023 | Interne | Passing Juice |
| June 2023 | Interne | Passing Juice |
| May 2023 | Interne | Passing Juice |
| April 2023 | Interne | Passing Juice |
| March 2023 | Interne | Passing Juice |
| February 2023 | Interne | Passing Juice |
| January 2023 | Interne | Passing Juice |
| December 2022 | Interne | Passing Juice |
| November 2022 | Interne | Passing Juice |
| October 2022 | Interne | Passing Juice |
| September 2022 | Interne | Passing Juice |
| August 2022 | Interne | Passing Juice |
| July 2022 | Interne | Passing Juice |
| June 2022 | Interne | Passing Juice |
| May 2022 | Interne | Passing Juice |
| April 2022 | Interne | Passing Juice |
| March 2022 | Interne | Passing Juice |
| February 2022 | Interne | Passing Juice |
| January 2022 | Interne | Passing Juice |
| November 2021 | Interne | Passing Juice |
| October 2021 | Interne | Passing Juice |
| September 2021 | Interne | Passing Juice |
| August 2021 | Interne | Passing Juice |
| July 2021 | Interne | Passing Juice |
| June 2021 | Interne | Passing Juice |
| May 2021 | Interne | Passing Juice |
| April 2021 | Interne | Passing Juice |
| March 2021 | Interne | Passing Juice |
| January 2021 | Interne | Passing Juice |
| December 2020 | Interne | Passing Juice |
| November 2020 | Interne | Passing Juice |
| October 2020 | Interne | Passing Juice |
| September 2020 | Interne | Passing Juice |
| August 2020 | Interne | Passing Juice |
| July 2020 | Interne | Passing Juice |
| June 2020 | Interne | Passing Juice |
| May 2020 | Interne | Passing Juice |
| April 2020 | Interne | Passing Juice |
| March 2020 | Interne | Passing Juice |
| February 2020 | Interne | Passing Juice |
| January 2020 | Interne | Passing Juice |
| December 2019 | Interne | Passing Juice |
| November 2019 | Interne | Passing Juice |
| October 2019 | Interne | Passing Juice |
| September 2019 | Interne | Passing Juice |
| August 2019 | Interne | Passing Juice |
| July 2019 | Interne | Passing Juice |
| May 2019 | Interne | Passing Juice |
| April 2019 | Interne | Passing Juice |
| March 2019 | Interne | Passing Juice |
| February 2019 | Interne | Passing Juice |
| January 2019 | Interne | Passing Juice |
| December 2018 | Interne | Passing Juice |
| November 2018 | Interne | Passing Juice |
| October 2018 | Interne | Passing Juice |
| September 2018 | Interne | Passing Juice |
| August 2018 | Interne | Passing Juice |
| July 2018 | Interne | Passing Juice |
| June 2018 | Interne | Passing Juice |
| May 2018 | Interne | Passing Juice |
| April 2018 | Interne | Passing Juice |
| March 2018 | Interne | Passing Juice |
| February 2018 | Interne | Passing Juice |
| January 2018 | Interne | Passing Juice |
| December 2017 | Interne | Passing Juice |
| November 2017 | Interne | Passing Juice |
| October 2017 | Interne | Passing Juice |
| September 2017 | Interne | Passing Juice |
| August 2017 | Interne | Passing Juice |
| July 2017 | Interne | Passing Juice |
| June 2017 | Interne | Passing Juice |
| May 2017 | Interne | Passing Juice |
| April 2017 | Interne | Passing Juice |
| March 2017 | Interne | Passing Juice |
| February 2017 | Interne | Passing Juice |
| January 2017 | Interne | Passing Juice |
| December 2016 | Interne | Passing Juice |
| November 2016 | Interne | Passing Juice |
| October 2016 | Interne | Passing Juice |
| September 2016 | Interne | Passing Juice |
| August 2016 | Interne | Passing Juice |
| July 2016 | Interne | Passing Juice |
| June 2016 | Interne | Passing Juice |
| May 2016 | Interne | Passing Juice |
| April 2016 | Interne | Passing Juice |
| March 2016 | Interne | Passing Juice |
| February 2016 | Interne | Passing Juice |
| January 2016 | Interne | Passing Juice |
| December 2015 | Interne | Passing Juice |
| November 2015 | Interne | Passing Juice |
| October 2015 | Interne | Passing Juice |
| September 2015 | Interne | Passing Juice |
| August 2015 | Interne | Passing Juice |
| July 2015 | Interne | Passing Juice |
| June 2015 | Interne | Passing Juice |
| May 2015 | Interne | Passing Juice |
| April 2015 | Interne | Passing Juice |
| March 2015 | Interne | Passing Juice |
| February 2015 | Interne | Passing Juice |
| January 2015 | Interne | Passing Juice |
| December 2014 | Interne | Passing Juice |
| November 2014 | Interne | Passing Juice |
| October 2014 | Interne | Passing Juice |
| September 2014 | Interne | Passing Juice |
| August 2014 | Interne | Passing Juice |
| July 2014 | Interne | Passing Juice |
| June 2014 | Interne | Passing Juice |
| May 2014 | Interne | Passing Juice |
| April 2014 | Interne | Passing Juice |
| March 2014 | Interne | Passing Juice |
| February 2014 | Interne | Passing Juice |
| January 2014 | Interne | Passing Juice |
| December 2013 | Interne | Passing Juice |
| November 2013 | Interne | Passing Juice |
| October 2013 | Interne | Passing Juice |
| September 2013 | Interne | Passing Juice |
| August 2013 | Interne | Passing Juice |
| July 2013 | Interne | Passing Juice |
| June 2013 | Interne | Passing Juice |
| May 2013 | Interne | Passing Juice |
| April 2013 | Interne | Passing Juice |
| March 2013 | Interne | Passing Juice |
| February 2013 | Interne | Passing Juice |
| January 2013 | Interne | Passing Juice |
| December 2012 | Interne | Passing Juice |
| November 2012 | Interne | Passing Juice |
| October 2012 | Interne | Passing Juice |
| September 2012 | Interne | Passing Juice |
| August 2012 | Interne | Passing Juice |
| July 2012 | Interne | Passing Juice |
| June 2012 | Interne | Passing Juice |
| May 2012 | Interne | Passing Juice |
| April 2012 | Interne | Passing Juice |
| March 2012 | Interne | Passing Juice |
| February 2012 | Interne | Passing Juice |
| January 2012 | Interne | Passing Juice |
| December 2011 | Interne | Passing Juice |
| November 2011 | Interne | Passing Juice |
| October 2011 | Interne | Passing Juice |
| September 2011 | Interne | Passing Juice |
| August 2011 | Interne | Passing Juice |
| July 2011 | Interne | Passing Juice |
| June 2011 | Interne | Passing Juice |
| May 2011 | Interne | Passing Juice |
| April 2011 | Interne | Passing Juice |
| March 2011 | Interne | Passing Juice |
| Privacy Policy | Interne | Passing Juice |
Mots-clefs
Nuage de mots-clefs
april ipo comment venture march biotech january year leave november
Cohérence des mots-clefs
| Mot-clef | Contenu | Titre | Mots-clefs | Description | Niveaux de titre |
|---|---|---|---|---|---|
| biotech | 42 |  |
 |
|
|
| ipo | 28 | |
|
|
|
| comment | 22 | |
|
|
|
| leave | 22 | |
|
|
|
| april | 21 | |
|
|
|
Ergonomie
Url
Domaine : lifescivc.com
Longueur : 13
Favicon
Génial, votre site web dispose d'un favicon.
Imprimabilité
Aucun style CSS pour optimiser l'impression n'a pu être trouvé.
Langue
Bien. Votre langue est : en.
Dublin Core
Cette page ne profite pas des métadonnées Dublin Core.
Document
Doctype
HTML 5
Encodage
Parfait. Votre charset est UTF-8.
Validité W3C
Erreurs : 0
Avertissements : 0
E-mail confidentialité
Attention! Au moins une adresse e-mail a été trouvée en texte clair. Utilisez une protection anti-spam gratuite pour cacher vos e-mails aux spammeurs.
HTML obsolètes
Génial! Nous n'avons pas trouvé de balises HTML obsolètes dans votre code.
Astuces vitesse
|
Excellent, votre site n'utilise pas de tableaux imbriqués. |
|
Mauvais, votre site web utilise des styles css inline. |
|
Mauvais, votre site web contient trop de fichiers CSS (plus de 4). |
|
Mauvais, votre site web contient trop de fichiers javascript (plus de 6). |
|
Parfait : votre site tire parti de gzip. |
Mobile
Optimisation mobile
|
Icône Apple |
|
Méta tags viewport |
|
Contenu FLASH |
Optimisation
Sitemap XML
Votre site web dispose d’une sitemap XML, ce qui est optimal.
| https://lifescivc.com/sitemap_index.xml |
Robots.txt
https://lifescivc.com/robots.txt
Votre site dispose d’un fichier robots.txt, ce qui est optimal.
Mesures d'audience
Votre site web dispose d’une outil d'analytics, ce qui est optimal.
Google Analytics |
PageSpeed Insights
Dispositif
Les catégories
Free SEO Testing Tool
Free SEO Testing Tool est un outil gratuit de référencement qui vous aidera à analyser vos pages web